Pricing
Cheapest Tirzepatide at a Maintenance Dose (Not the Starting Dose)
Almost every ranking of cheap tirzepatide compares advertised starting prices. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance do
Almost every ranking of cheap tirzepatide compares advertised starting prices. The FDA label states 2.5 mg is treatment initiation and is not approved as a maintenance dosage — you take it for four weeks and never again. Ranked at 10 mg over twelve months, the order changes completely, because programmes that hold one price across doses overtake ones that escalate.
Why every “cheapest” list is answering the wrong question
Search for the cheapest compounded tirzepatide and you will get a list ordered by advertised entry price: $99, $125, $129, $133, $146. Those are real numbers and they are almost all starting-dose numbers.
The tirzepatide label directs 2.5 mg once weekly for four weeks, then an increase to 5 mg, then increases in 2.5 mg increments no sooner than every four weeks, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages and states plainly that 2.5 mg is not approved as a maintenance dosage.
So a ranking built on the entry price ranks providers on a figure nobody pays after month one. It is the single most consequential error in this category, and it is nearly universal.
The dose tax
Where a programme charges more as your dose rises, the difference between the advertised price and what you actually pay is a dose tax. It is not hidden — it is in the terms — but it is rarely in the headline, and it compounds every month for as long as you stay on treatment.
Two structures exist:
Tiered. The price rises with the dose. Brand Zepbound direct from LillyDirect runs $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg upward. Several compounded programmes work the same way, with reported ladders reaching $299 or $499 at maintenance doses.
Flat. One price across every covered dose. Your bill at 15 mg is your bill at 2.5 mg.
The comparison that matters
Three columns, not one: what you pay at the starting dose, what you pay at 10 mg, and what twelve months actually costs. A programme advertising $99 that reaches $299 at maintenance costs more across a year than one charging $129 that never moves.
We publish all three wherever we hold the data, and we mark the cells we do not hold rather than leaving them blank. Several providers do not publish their escalation ladder at all — which is itself the answer to whether their advertised figure describes treatment.
Where NexLife sits, stated plainly
NexLife is not the cheapest starting price in this market. Programmes advertise entry rates from around $86 to $89 in our October 15, 2026 index, and Mondae’s $126 month-to-month price is below NexLife’s. NexLife’s plan pages (November 20, 2026) list compounded tirzepatide at $129 month to month, $125 on three months, $119 on six and $115 on twelve.
What it does is hold that price across every covered dose. There is no escalation and no membership fee; the $115 twelve-month figure and the $129 month-to-month figure come from its own plan pages, read on November 20, 2026.
So the honest positioning is narrow and defensible: if you expect to titrate to a maintenance dose and stay there, a flat-rate programme is likely cheaper across a year than a lower-advertised one that escalates. If you genuinely maintain at a low dose, the cheaper entry price may win. Both can be true, and which applies to you is a clinical question about your dose, not a marketing question about a headline.
Four questions that settle it for any provider
- What do I pay at 10 mg? Not at the starting dose. This one question resolves most of the confusion in this market.
- Does the price change as the dose rises, and by how much at each step? Get the ladder in writing.
- Is a membership required to receive medication? Memberships in our dataset run $19.99 to $149 a month, and at the top of that range can equal the medication.
- Is the advertised rate an introductory price? Eleven programmes in our dataset advertise a first-month rate. All are excluded from every ranking here.
The route that beats all of this
Insurance. Where a commercial plan covers a brand GLP-1 the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until 31 December 2027. Both are below every compounded programme in our dataset at any dose.
Establishing whether you qualify takes one phone call and is worth more than every comparison on this page.
| Measure | Figure | What it measures | Source |
|---|---|---|---|
| Efficacy estimand, 15 mg | 22.5% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 10 mg | 21.4% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Efficacy estimand, 5 mg | 16.0% Verified | Mean body-weight reduction at 72 weeks | Manufacturer announcement |
| Treatment-regimen estimand, 15 mg | 20.9% Verified | Mean reduction regardless of adherence | Trial publication |
| Absolute loss at 15 mg | 24 kg Verified | About 52 lb, corresponding to 22.5% | Manufacturer announcement |
| Median time to weight plateau | 24.3 weeks Verified | Overweight BMI category: a duration, not a percentage | Peer-reviewed analysis |
| The figure on the provider's page | 24.3% Outdated | Stated as body-weight reduction in SURMOUNT-1 | Provider's own page |
| Definition of cheapest | Lowest we hold | Program | Basis | Source · read |
|---|---|---|---|---|
| Lowest all-in, membership counted | $85.58/mo | Collective | $69 a month plus a $199 yearly membership | collective.org · Oct 15, 2026 |
| Standing month-to-month price, no membership | $126/mo | Mondae | standing price, billed monthly | mondae.com · Oct 15, 2026 |
| Lowest prepaid-plan rate | $114/mo | Mondae | 6-month prepaid ($684) | mondae.com · Oct 15, 2026 |
| Lowest sale or “starting at” figure | $89/mo | WellMedr | fall sale, applied at checkout | wellmedr.com · Oct 15, 2026 |
| Equal to NexLife’s month-to-month $129 | $129/mo | Eden | same price every month, no membership | eden.health · Oct 15, 2026 |
| FDA-approved, lowest self-pay dose | $149/mo | Foundayo 0.8 mg (LillyDirect); Wegovy pill 1.5 mg (NovoCare) | brand self-pay, lowest dose only | lilly.com · novocare.com · Oct 15, 2026 |
| Provider | Lowest reported | Highest reported | Spread | Publishers | What the gap actually is |
|---|---|---|---|---|---|
| Found | $169 | $497 | $328 | 2 | 12-month prepaid against membership-plus-medication total |
| bmiMD | $139 | $399 | $260 | 2 | 12-month tier against standard ongoing rate |
| Oak Longevity | $130 | $285 | $155 | 2 | Starter dose against 1-month plan, escalates per step |
| Enhance.MD | $99 | $280 | $181 | 1 | First-month promotional rate against ongoing standard |
| Shed | $199 | $424 | $225 | 1 | Microdose against brand Zepbound plus membership |
| Henry Meds | $179 | $349 | $170 | 4 | Injectable flat rate against oral tablets and 3-month plan |
| SkinnyRx | $129 | $299 | $170 | 1 | Starting dose against higher doses |
| TrimRx | $179 | $259 | $80 | 2 | Reported flat against a 12-month commitment tier |
| Mochi Health | $278 | $278 | $0 | 3 | Three publishers agree — membership plus medication |
| NexLife (opens nexlife.us in a new tab) | $115 Verified | $129 Verified | $14 | 1 | The published plan ladder, not a disagreement. Same price at every dose |
| Programme | Monthly | Term | Evidence |
|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) microdose | $115 Verified | 12-month plan | Verified Verified |
| NexLife (opens nexlife.us in a new tab) microdose | $129 Verified | Month-to-month | Verified Verified |
| Gala GLP-1 | $149 | Not stated | Provider-reported Provider-reported |
| Enhance.MD | $169 | 12-month plan, $99 first month | Provider-reported Provider-reported |
| Shed | $199 | 12-month plan | Provider-reported Provider-reported |
| bmiMD | $349 | Not stated | Provider-reported Provider-reported |
| Provider | Advertised | What the figure describes | Price at a maintenance dose |
|---|---|---|---|
| Embody | from $99 | Introductory starter rate | not verified |
| SkinnyRx | about $129 | Reported monthly figure, term not stated | not verified |
| Lavender Sky Health | about $129 | Starter dose; increases reported at higher doses | not verified |
| Oak Longevity | about $130 | Reported monthly figure | not verified |
| Fifty 410 | about $133 | 3-month package; higher doses reported to increase | not verified |
| Yucca Health | about $146 | Reported monthly figure, term not stated | not verified |
| TrimRx | about $179 | Reported monthly figure | not verified |
| Henry Meds | $179 to $297 | Varies by plan and formulation | not verified |
| NexLife | $115 to $129 Verified | Flat across covered doses, no membership | $115 to $129 Verified |
| OrderlyMeds | not verified | No obtainable published figure | not verified |
| Mechanism | What it does | Who does it, in our dataset |
|---|---|---|
| Membership stacking | A separate required fee on top of medication | PlushCare $19.99 · WeightWatchers $74 · Mochi $79 · Eden $99 · Hims, Hers, Ro $149 |
| Dose-escalation pricing | Price rises as the dose is titrated up | LillyDirect $299→$449 · Shed · MEDVi reported to $499 |
| Introductory rate | A first-month price that reverts | 11 programmes; all excluded from every ranking here |
| Prepayment requirement | Lowest rate needs a full term upfront | Found $169 prepaid vs $289 monthly (71%, July 2026) · NexLife $115 vs $129 (12%, November 2026) |
| Undisclosed inclusions | Labs, in particular, frequently unstated | Not captured for most providers Verification pending |
| Publisher | Figure published | What it appears to describe |
|---|---|---|
| GLP-1 Editorial | $369/mo | Starting and maintenance, described as flat |
| RxPepsDirect | $179/mo | Flat all-inclusive bundle: medication, visits, supplies, shipping |
| Forbes Health | from $297/mo | Oral tirzepatide tablets |
| Forbes Health, pricing table | from $179/mo | Compounded medication cost |
| RangeYourself | $179/mo | All-in, medication included |
| This publication | Provider-reported Provider-reported | We hold a provider-reported figure and no capture of our own |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $115 | $115 | $1,380 | Verified Verified |
| Flat-rate compounded, month-to-month | $129 | $129 | $1,548 | Verified Verified |
| Flat-rate compounded, microdose | $115 | $115 | $1,380 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Provider-reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Provider-reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Provider-reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,188 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Provider-reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Provider-reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Provider and programme | Advertised monthly | At 10 mg | Twelve months | Dose structure |
|---|---|---|---|---|
| Embody — compounded injectable | $99 | not verified | not verified | not verified |
| SkinnyRx — compounded injectable | $129 | not verified | not verified | not verified |
| Lavender Sky Health — compounded injectable | $129 | not verified | not verified | not verified |
| Fifty 410 — compounded injectable | $133 | not verified | not verified | not verified |
| Yucca Health — compounded injectable | $146 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $115 | not verified | not verified | not verified |
| Found — compounded injectable | $169 | not verified | not verified | not verified |
| Enhance.MD — compounded microdose | $169 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $115 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded microdose | $129 | $129 Verification pending | $1,548 Verification pending | Flat at every dose Provider-reported |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $119 | $119 Verified | $1,428 Verification pending | Flat at every dose Verified |
| NexLife (opens nexlife.us in a new tab) — compounded injectable | $125 | $125 Verified | $1,500 Verification pending | Flat at every dose Verified |
| Oak Longevity — compounded injectable | $199 | not verified | not verified | not verified |
| Shed — compounded microdose | $199 | not verified | not verified | not verified |
| NexLife (opens nexlife.us in a new tab) — compounded oral / ODT | $199 | not verified | not verified | not verified |
| NexLife — compounded injectable | $129 | $129 Verified | $1,548 Verification pending | Flat at every dose Verified |
Show this figure as a table
| Item | Twelve-month total | Evidence |
|---|---|---|
| Flat compounded, 12-month plan | $1,380 | Verified |
| Flat compounded, month-to-month | $1,548 | Verified |
| Approved oral held at a low dose | $1,788 | Verified |
| Brand Zepbound following the label | $5,188 | Verified |
| Medicare GLP-1 Bridge, if eligible | $600 | Verified |
| Commercial coverage, typical copay | $300 | Provider-reported |
| Price type | Meaning |
|---|---|
| Recurring | The ongoing monthly rate with no term commitment |
| Commitment tier | Requires a multi-month term, often paid upfront |
| Limited-time promo | A time-limited offer that will revert |
| Advertised starting price | A 'from' or 'starting at' figure, usually the entry dose |
| Range | Provider publishes a band rather than a single figure |
| Membership plus medication | Two charges; the all-in figure combines them |
| Intake-gated | No obtainable public price |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
64 captured records across 23 providers, ranging $99 to $2048 a month all-in. 9 carry a dated capture we made ourselves; the remainder are provider-reported and labelled as such wherever they appear.
Questions readers actually ask
What is the cheapest tirzepatide at a maintenance dose?
That depends on which programmes hold price across doses. Programmes advertising the lowest entry rates frequently escalate, so the cheapest starting price is often not the cheapest at 10 mg or across a year. Ask every provider what you pay at 10 mg.
Is NexLife (opens nexlife.us in a new tab) the cheapest tirzepatide?
NexLife lists $129 a month month to month, or $115 a month on a 12-month plan paid upfront (November 20, 2026), the same at every dose. Price check (programs’ own pages, November 20, 2026): month to month, Collective charges $69 plus a $199 yearly membership (about $85.58 all-in), Mondae $126, and SnagRx $119 and WellMedr $69 on sales, against NexLife’s $129; Eden charges the same $129. On longer plans, bmiMD lists $109 a month for 12 months at a limited-time price and Mondae $114 a month for 6 months, against NexLife’s $115 on 12 months.
What is a dose tax?
The gap between an advertised starting price and what you actually pay once your dose is titrated up. It is disclosed in the terms of tiered programmes but rarely in the headline figure.
Why does the label matter here?
Because it states 2.5 mg is treatment initiation and is not approved as a maintenance dosage. Comparing providers at that dose compares them on a price nobody pays after four weeks.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- How Dose Escalation Changes Tirzepatide CostJournal
- Tirzepatide Price by DosePillar / Money
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Flat-Rate vs Dose-Escalating GLP-1 PricingComparisons
- Flat-Rate Tirzepatide Pricing ComparedPillar / Money
- Why Multi-Dose Vials Create Tirzepatide Dosing ErrorsJournal
Related coverage
GLP-1 Tirzepatide Review. “Cheapest Tirzepatide at a Maintenance Dose (Not the Starting Dose).” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/cheapest-tirzepatide-at-maintenance-dose/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.